Catheter Precision Stock Price, News & Analysis

Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology products, has set September 10th, 2025 as the record date for its upcoming Special Meeting of Stockholders scheduled for October 10th, 2025.

During the meeting, stockholders will vote on two key proposals: increasing the company's authorized shares of common stock and appointing WithumSmith+Brown, PC as the independent auditor for fiscal year 2026. The preliminary proxy statement detailing these matters is expected to be filed with the SEC on September 4th, 2025.

Catheter Precision (NYSE:VTAK) has announced the successful introduction of its LockeT product line into the Italian market, marking its third European country expansion following France and Germany. The first procedures were successfully conducted at ASST Valle Olona Hospital by Dr. Manuela Bianchi.

The company received its first commercial purchase order from Italian distributor Precise Srl following successful product evaluation. This expansion demonstrates growing market acceptance of LockeT, a device designed to streamline closure after catheter ablation procedures while maintaining cost-effectiveness.

Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT procedures in France at CHU Rennes. The procedures were led by Professor Raphael Martins and his team, marking a significant milestone in the company's European expansion.

This development follows the recent CE Mark approval for LockeT, a device designed to improve procedural efficiency and patient outcomes after cardiac ablation procedures. CHU Rennes, which is also a commercial partner for VTAK's VIVO product line, represents the company's growing presence in the European medical device market.

Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology products, has received notification for a new patent issuance from the U.S. Patent and Trademark Office. The patent, titled "Methods of Ventricular Arrhythmia Localization Using a 3D Heart Model," enhances the company's VIVO product line.

The new patent adds to Catheter Precision's existing IP portfolio for VIVO, which is designed to help physicians identify ventricular arrhythmias noninvasively before procedures. CEO David Jenkins emphasized the importance of patents and trademarks in their business strategy and their commitment to advancing medical technology for improved patient care.

Catheter Precision (NYSE:VTAK) has initiated enrollment in the LockeT Compare Study, with the first three patients already enrolled. This single-center, physician-initiated study aims to evaluate the safety profile of the LockeT suture retention device compared to internal closure devices.

The study will enroll up to 100 patients and focuses on addressing groin complications after cardiac catheter procedures. Previous clinical data for LockeT has demonstrated safety, effectiveness, and cost reduction benefits while maintaining existing hospital workflows. The device creates hemostasis externally and may potentially reduce thrombotic episodes compared to internal closure mechanisms.

Catheter Precision (NYSE:VTAK) has received regulatory approval for its LockeT suture retention device in the United Kingdom, following its CE Mark approval in May 2025. The company has partnered with HC21, a major UK-based distributor with €180 million in annual revenue and 500+ employees across the UK and Ireland.

The LockeT device is designed to enhance patient comfort, enable earlier discharge after cardiac procedures, and support NHS efforts to reduce waiting lists. The company will distribute the product through HC21's established network, leveraging their existing partnership to bring the innovative cardiac device to the UK healthcare market.

Catheter Precision (NYSE American: VTAK), a medical device company specializing in cardiac electrophysiology products, has implemented a 1-for-19 reverse stock split effective August 15, 2025. The split will reduce the company's outstanding common shares from 23,316,520 to approximately 1,657,640.

The stock will continue trading under the symbol "VTAK" with a new CUSIP number 74933X708. Proportional adjustments will be made to equity awards, warrants, and other convertible securities. No fractional shares will be issued; instead, stockholders entitled to fractional shares will receive pro-rata proceeds from their sale.

Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT cases in Germany at Zentralklinik Bad Berka, one of Thuringia's largest hospitals.

The medical team has successfully conducted 10 cases using LockeT to close single or multiple punctures with a single device per case. The procedures demonstrated LockeT's versatility by handling sheath sizes ranging from 6F to 17Fr. The company views Germany as a significant European market opportunity, particularly due to its price-conscious nature.

Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology, reported significant growth in Q2 2025. Revenue surged 128% year-over-year to $212,000 and 48% sequentially. The company achieved several milestones, including receiving CE Mark for LockeT and completing strategic acquisitions.

Notable clinical achievements include successful trials demonstrating VIVO's 94% accuracy in non-invasive localization and 83% long-term procedural success. The company formed Kardionav, Inc. for developing implant-based software for ventricular tachyarrhythmia treatment. However, the company reported a net loss of $5.4 million for Q2 2025, with $3.2 million in non-cash charges, and maintained a cash position of $838,000.